Sign in →

Test ID MYCPN Mycoplasma pneumoniae Antibodies, IgG and IgM, Serum

Useful For

An aid in the diagnosis of disease associated with Mycoplasma pneumoniae

Profile Information

Test ID Reporting Name Available Separately Always Performed
MYCG M. pneumoniae Ab, IgG, S No Yes
MYCM M. pneumoniae Ab, IgM, S No Yes

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
MMYCO M. pneumoniae Ab, IgM, S by IFA No No

Testing Algorithm

If Mycoplasma pneumoniae antibodies, IgM is positive or equivocal, then Mycoplasma pneumoniae antibodies, IgM by indirect immunofluorescence assay (IFA) will be performed at an additional charge.

Method Name

MYCG, MYCM: Enzyme Immunoassay (EIA)

MMYCO: Indirect Immunofluorescence Assay (IFA)

Reporting Name

M. pneumoniae Ab, IgG and IgM, S

Specimen Type

Serum

Collection Container/Tube: 

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 1 mL

Specimen Minimum Volume

0.5 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Refrigerated (preferred) 14 days
  Frozen  14 days

Clinical Information

Mycoplasma pneumoniae is an important respiratory tract pathogen.

 

Several syndromes have been associated with the infection including pharyngitis, tracheobronchitis, pneumonia, and inflammation of the tympanic membrane presenting as bullous myringitis.  

                                        

Mycoplasma pneumoniae accounts for approximately 20% of all cases of pneumonia. Classically, it causes a disease that has been described as primary atypical pneumonia. The disease is of insidious onset with fever, headache, and malaise for 2 to 4 days before the onset of respiratory symptoms. Most cases do not require hospitalization. Symptomatic infections attributable to this organism most commonly occur in children and young adults (ages 2-19 years).(1)

Reference Values

IgG

≤0.90 (negative)

0.91-1.09 (equivocal)

≥1.10 (positive)

 

IgM

≤0.90 (negative)

0.91-1.09 (equivocal)

≥1.10 (positive)

 

IgM by IFA

Negative (reported as positive or negative)

Cautions

A diagnosis should not be made on the basis of antimycoplasma results alone. Test results should be interpreted in conjunction with the clinical evaluation and the results of other diagnostic procedures.

 

The use of hemolytic, lipemic, bacterially contaminated, or heat-inactivated specimens should be avoided as erroneous results may occur.

 

Assay performance characteristics have not been established for matrices other than serum.

 

The continued presence or absence of antibodies cannot be used to determine the success or failure of therapy.

 

Testing should not be performed as a screening procedure for the general population. Testing should only be done when clinical evidence suggests the diagnosis of Mycoplasma pneumoniae-associated disease.

 

The performance of this test has not been established on neonates and immunocompromised patients.

 

Performance of the IgM assay has not been tested with specimens known to be positive for antibodies to organisms that are known to be associated with lower respiratory illness (ie, influenza A and B, cytomegalovirus, Chlamydophila pneumoniae, parainfluenza), and closely related serovars known to cross-react with Mycoplasma pneumoniae, such as Mycoplasma genitalium and Mycoplasma hominis, as well as various Ureaplasma species. Cross-reactivity studies with such organisms have not been performed with this assay.

 

The IgG removal system included with the IgM test system has been shown to functionally remove the IgG from specimens containing total IgG levels ranging from 300 to 600 mg/mL. The effectiveness of this removal system at IgG levels exceeding 600 mg/mL has not been established.

 

The prevalence of Mycoplasma IgM antibody is relatively low, which affects the assay's predictive value.

Day(s) Performed

Monday through Friday; 9 a.m.

Report Available

Same day/1 day

Performing Laboratory

Mayo Medical Laboratories in Rochester

Test Classification

This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

86738 x 2-Mycoplasma pneumoniae by EIA

86738-Mycoplasma pneumoniae by indirect IFA (if appropriate)

NY State Approved

Yes